415 related articles for article (PubMed ID: 20350661)
1. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
3. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
4. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.
Else M; Marín-Niebla A; de la Cruz F; Batty P; Ríos E; Dearden CE; Catovsky D; Matutes E
Br J Haematol; 2012 Nov; 159(3):322-8. PubMed ID: 23016878
[TBL] [Abstract][Full Text] [Related]
5. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
Olszewski AJ; Ali S
Ann Hematol; 2014 Mar; 93(3):449-58. PubMed ID: 24057925
[TBL] [Abstract][Full Text] [Related]
6. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
7. [Splenic marginal zone lymphoma associated with autoimmune hemolytic anemia treated with splenectomy and rituximab].
Miztani M; Noda T; Umino A; Tanigawa M; Taniguchi M; Tamaki S; Tsuji K
Rinsho Ketsueki; 2007 Nov; 48(11):1489-91. PubMed ID: 18080507
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
9. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?
Kalpadakis C; Pangalis GA; Vassilakopoulos TP; Sachanas S; Angelopoulou MK
Leuk Lymphoma; 2014 Jul; 55(7):1463-70. PubMed ID: 24050506
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
Tsimberidou AM; Catovsky D; Schlette E; O'Brien S; Wierda WG; Kantarjian H; Garcia-Manero G; Wen S; Do KA; Lerner S; Keating MJ
Cancer; 2006 Jul; 107(1):125-35. PubMed ID: 16700034
[TBL] [Abstract][Full Text] [Related]
11. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.
Xing KH; Kahlon A; Skinnider BF; Connors JM; Gascoyne RD; Sehn LH; Savage KJ; Slack GW; Shenkier TN; Klasa R; Gerrie AS; Villa D
Br J Haematol; 2015 May; 169(4):520-7. PubMed ID: 25854936
[TBL] [Abstract][Full Text] [Related]
12. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.
Iannitto E; Minardi V; Calvaruso G; Ammatuna E; Florena AM; Mulè A; Tripodo C; Quintini G; Abbadessa V
Eur J Haematol; 2005 Aug; 75(2):130-5. PubMed ID: 16000129
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma.
Olszewski AJ
Am J Hematol; 2012 Nov; 87(11):E119-22. PubMed ID: 22887176
[TBL] [Abstract][Full Text] [Related]
14. [Progress on Treatment of Splenic Marginal Zone Lymphoma-Review].
Wu L; Tian C; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):600-603. PubMed ID: 28446319
[TBL] [Abstract][Full Text] [Related]
15. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
16. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
17. Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?
Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Vassilakopoulos TP
Best Pract Res Clin Haematol; 2018 Mar; 31(1):65-72. PubMed ID: 29452668
[TBL] [Abstract][Full Text] [Related]
18. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
Thieblemont C; Felman P; Berger F; Dumontet C; Arnaud P; Hequet O; Arcache J; Callet-Bauchu E; Salles G; Coiffier B
Clin Lymphoma; 2002 Jun; 3(1):41-7. PubMed ID: 12141954
[TBL] [Abstract][Full Text] [Related]
19. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.
Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Kontopidou FN; Yiakoumis X; Kokoris SI; Dimitriadou EM; Dimopoulou MN; Moschogiannis M; Korkolopoulou P; Kyrtsonis MC; Siakantaris MP; Papadaki T; Tsaftaridis P; Plata E; Papadaki HE; Vassilakopoulos TP
Oncologist; 2013; 18(2):190-7. PubMed ID: 23345547
[TBL] [Abstract][Full Text] [Related]
20. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
